Compare Schwab US Dividend Equity ETF (SCHD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Dividend Equity ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Schwab US Dividend Equity ETF trades at $33.98 (market cap $111.61B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Schwab US Dividend Equity ETF is far larger — about 15.2× Spyre Therapeutics Inc. Common Stock's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Dividend Equity ETF for 64 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SCHD | SYRE | |
|---|---|---|
Market Cap | $111.61B | $7.35B |
Volume | 25,598,052 | 1,624,631 |
Sector | Broad Market / Factor | Health |
52-Week High | $35.21 | $108.92 |
52-Week Low | $26.44 | $22.18 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHD trades at $33.37, up 0.33% on the day, with a bullish technical signal driven by moving averages. The ETF's dividend-focused strategy is highlighted in recent news, with articles noting its outperformance against the S&P 500 in 2026 and its appeal for income investors. Key support and resistance cluster around $33, while RSI levels show mixed momentum signals.
Outlook remains positive for dividend growth and defensive positioning, but risks include interest rate sensitivity and potential missed gains from strict stock selection rules. Investors benefit from lower fees and rising payouts, though macroeconomic shifts could pressure yields.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
